{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:48Z","timestamp":1707524328988},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"DOI":"10.7759\/cureus.15835","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T16:54:28Z","timestamp":1624380868000},"source":"Crossref","is-referenced-by-count":0,"title":["Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn\u2019s Disease"],"prefix":"10.7759","author":[{"given":"Aswani","family":"Thurlapati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siva Santosh Kumar","family":"Gandu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreedhar","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000667","article-title":"Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis","volume":"4","author":"Alivernini S","year":"2018","unstructured":"Alivernini S, Pugliese D, Tolusso B, et al.. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open. 2018, 4:e000667. 10.1136\/rmdopen-2018-000667","journal-title":"RMD Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German perspective, open-label, multicenter trial in refractory Crohn\u2019s disease","volume":"97","author":"Herfarth H","year":"2002","unstructured":"Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, Schreiber S. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German perspective, open-label, multicenter trial in refractory Crohn\u2019s disease. Am J Gastroenterol. 2002, 97:2688-90. 10.1111\/j.1572-0241.2002.06064.x","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn's disease","volume":"25","author":"Kaufman I","year":"2005","unstructured":"Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005, 25:406-10. 10.1007\/s00296-004-0467-8","journal-title":"Rheumatol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen G","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz A, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011, 34:1318-27. 10.1111\/j.1365-2036.2011.04866.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier JF","year":"2010","unstructured":"Rahier JF, Buche S, Peyrin-Biroulet L, et al.. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010, 8:1048-55. 10.1016\/j.cgh.2010.07.022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","article-title":"Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors","volume":"59","author":"Cleynen I","year":"2010","unstructured":"Cleynen I, Van Moerkercke W, Juergens M, Ballet V, Drobne D, Vandecandelaere P. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut. 2010, 59:A1.","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire S","year":"2003","unstructured":"Vermeire S, Noman M, Van Assche G, et al.. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003, 125:32-9. 10.1016\/s0016-5085(03)00701-7","journal-title":"Gastroenterology"},{"key":"ref8","unstructured":"Johns Hopkins Arthritis Center. In Crohns Disease, the Development of Antibodies to Infliximab (Remicade) Is Associated with Shorter Duration of Clinical Response and More Infusion Reactions. (2005). Accessed. June 22, 2021: https:\/\/www.hopkinsarthritis.org\/arthritis-news\/in-crohns-disease-the-development-of-antibodies-to-infliximab-remicad...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel JF","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al.. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010, 362:1383-95. 10.1056\/NEJMoa0904492","journal-title":"N Engl J Med"},{"key":"ref10","article-title":"Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response","volume":"8","year":"2012","unstructured":"Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response. Gastroenterol Hepatol (N Y). 2012, 8.131-4.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000456940.26204.e8","article-title":"Effective management of autoimmune arthralgia arising from anti-TNF","author":"Sharon D-B","year":"2014","unstructured":"Sharon D-B. Effective management of autoimmune arthralgia arising from anti-TNF. Inflamm Bowel Dis. 2014, S89. 10.1097\/01.MIB.0000456940.26204.e8","journal-title":"Inflamm Bowel Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21909","article-title":"Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose","volume":"18","author":"Ally MR","year":"2012","unstructured":"Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis. 2012, 18:E1592-3. 10.1002\/ibd.21909","journal-title":"Inflamm Bowel Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda G","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al.. Crohn's disease. Nat Rev Dis Primers. 2020, 6:22. 10.1038\/s41572-020-0156-2","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al.. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019, 381:1215-26. 10.1056\/NEJMoa1905725","journal-title":"N Engl J Med"},{"key":"ref15","unstructured":"Managing Checkpoint Inhibitor-Mediated Colitis. Vedolizumab vs Infliximab. (2020). Accessed: December 24, 2020: https:\/\/ascopost.com\/issues\/december-10-2020\/managing-checkpoint-inhibitor-mediatedcolitis\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/55749-paradoxical-arthralgia-secondary-to-anti-tumor-necrosis-factor-alpha-therapy-in-crohns-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:19Z","timestamp":1707506719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/55749-paradoxical-arthralgia-secondary-to-anti-tumor-necrosis-factor-alpha-therapy-in-crohns-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.15835","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}